Pharmaceutical companies have enjoyed prosperous years under Republican-controlled Congress. However, the most recent midterm election evoked a sweeping change in the political climate. Democrats hold a number of agenda items that scare the pharmaceutical industry. They want to investigate drug pricing and profits, drug advertising aimed at consumers, and the marketing of drugs to doctors for purposes not intended by the FDA.
Hoping to prevent Congress from negotiating lower drug prices for older Americans on Medicare, the pharmaceutical companies have been taking defensive actions. They have actively recruited more Democratic lobbyists, lined up allies in the Bush administration and Congress, and renewed ties with organizations of patients who require brand-name drugs.
For the full article.